Recent Quotes (30 days)

You have no recent quotes
chg | %

Novadaq Technologies Inc.  

(Public, TSE:NDQ)   Watch this stock  
Find more results for NDQ
9.78
+0.28 (2.95%)
Dec 8 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 9.43 - 9.78
52 week 9.43 - 20.40
Open 9.43
Vol / Avg. 4,855.00/7,224.00
Mkt cap 539.61M
P/E     -
Div/yield     -
EPS -1.01
Shares 57.44M
Beta 0.68
Inst. own     -
Nov 30, 2016
Novadaq Technologies Inc at Piper Jaffray Healthcare Conference
Nov 17, 2016
Novadaq Technologies Inc at Canaccord Genuity Med Tech Conference
Nov 14, 2016
Novadaq Technologies Inc Corporate Analyst Meeting - Investor Day
Oct 28, 2016
Q3 2016 Novadaq Technologies Inc Earnings Release (Estimated)
Sep 12, 2016
Novadaq Technologies Inc at Morgan Stanley Global Healthcare Conference - Webcast
  

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -49.17% -48.31%
Operating margin -49.35% -56.47%
EBITD margin - -45.74%
Return on average assets -28.26% -16.54%
Return on average equity -32.48% -20.19%
Employees 56 -
CDP Score - -

Address

5090 Explorer Dr Suite 202
MISSISSAUGA, ON L4W 4T9
Canada
+1-905-6293822 (Phone)
+1-905-6290282 (Fax)

Website links

Description

Novadaq Technologies Inc. is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed. The Company's segment is medical devices. The Company's SPY fluorescence imaging technology platform (SPY Fluorescence Imaging) provides clinically relevant anatomic and physiologic images of blood flow in vessels and micro-vessels during a range of surgical and outpatient procedures performed in the operating room or clinic. The Company's products include SPY, SPY Elite, LUNA and PINPOINT Imaging Systems, SPY Analysis Toolkit, DermACELL and SPY-Q Case Manager. DermACELL is an Acellular Dermal Matrix (ADM) that is used in breast reconstruction surgeries, as well as in the treatment of diabetic foot and venous stasis ulcers, and chronic non-healing wounds.

Officers and directors

William A. MacKinnon Chairman of the Board
Age: 69
Rick Mangat Ph.D. President, Chief Executive Officer
Roger Deck Chief Financial Officer
Lori Swalm Vice President of Marketing
Derrick Guo General Counsel, Corporate Secretary
Anthony F. Griffiths Lead Independent Director
Age: 85
Karen A. Licitra Director
Patrice E. Merrin Independent Director
Age: 67
Thomas G. Wellner Independent Director
Age: 51
Robert S. White Independent Director
Age: 54